source: European Cardiology Review
Abstract
Objective: CYP2C19 is the hepatic enzyme involved in biotransformation of clopidogrel to its active metabolite. Polymorphism of CYP2C19 genes would jeopardise clopidogrel's efficacy as an antiplatelet agent. We aim to gain genetic polymorphism data of the CYP2C19 gene from patients with coronary artery disease undergoing PCI.
Concepts :
Pharmacogenetics and Drug Metabolism
Hormonal Regulation and Hypertension
Eicosanoids and Hypertension Pharmacology
review
cite 1
Year 2021
source European Cardiology Review